Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab, Toripalimab, and Irinotecan in Refractory Right-Sided mCRC (CITRUS)
NCT06547203Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2024
- Primary completion
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of KL-140, toripalimab in metastatic colorectal cancer (mCRC), sponsored by Sun Yat-sen University. Started Jul 2024; status: recruiting.
02
Drugs
KL-140toripalimab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06547203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06547203.